Searchable abstracts of presentations at key conferences in endocrinology

ea0073s12.3 | Symposium 12: What's new in cardiovascular protection and function | ECE2021

Role of inflammation in the therapy of cardiometabolic diseases

Donath Marc Y

Morphological and therapeutic interventions have uncovered an inflammatory process in patients with type 2 diabetes. This inflammation is due to a pathological activation of the innate immune system by metabolic stress and is largely governed by IL-1 signaling. Initially, the inflammatory response is probably deployed to promote adaptation and regeneration. Indeed, we identified a role for IL-1β and insulin in the regulation of both metabolism and immunity in response to ...

ea0049oc11.3 | Obesity | ECE2017

Interleukin-1 antagonism decreases cortisol levels in obese individuals

Urwyler Sandrine , Schutz Philipp , Ebrahimi Fahim , Donath Marc Y. , Christ-Crain Mirjam

Background: Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). We therefore hypothesised that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal (HPA) axis, leading to decreased cortisol levels.Methods: I...

ea0049ep687 | Obesity | ECE2017

Effects of IL-1β on the hypothalamic-pituitary-gonadal axis in men with obesity and metabolic syndrome – A randomized, double-blind, placebo-controlled trial

Ebrahimi Fahim , Schuetz Philipp , Mueller Beat , Urwyler Sandrine A , Donath Marc Y , Christ-Crain Mirjam

Background: Low testosterone levels in men appear to be an independent cardiovascular risk factor closely associated with the metabolic syndrome. Reciprocally, the metabolic syndrome leads to a decrease in testosterone levels, suggesting a bidirectional relationship. It has been hypothesized that increased inflammation is causative for the development of obesity-associated hypogonadism. However, clinical evidence supporting this hypothesis is lacking. The aim of the present st...

ea0063gp133 | Obesity | ECE2019

Effect of IL1-receptor antagonist on renin-angiotensin-aldosterone system and hemodynamics in obese individuals

Urwyler Sandrine , Ebrahimi Fahim , Burkard Thilo , Schuetz Philipp , Poglitsch Marko , Beat Mueller , Donath Marc Y , Christ-Crain Mirjam

Background: Interleukin (IL)-1 antagonism decreases systolic blood pressure in obese individuals. However, the underlying mechanism is unknown. Based on experimental data in animals we hypothesised a blood-pressure lowering effect of IL-1-antagonism via modulation of the renin-angiotensin-aldosterone system (RAAS).Methods: In this post-hoc explorative study, we examined short- (2 days) and long-term effects (4 weeks) of IL-1 antagonism (anakinra/Kineret<...

ea0041oc3.2 | Diabetes prediction &amp; complications | ECE2016

Glucose-dependent insulinotropic peptide (GIP) stimulates Glucagon-like peptide (GLP)-1 from human and mouse pancreatic islets partly via alpha-cell-derived IL-6

Timper Katharina , Dalmas Elise , Dror Erez , Rutti Sabine , Thienel Constanze , Sauter Nadine S. , Bouzakri Karim , Bedat Benoit , Pattou Francois , Kerr-Conte Julie , Boni-Schnetzler Marianne , Donath Marc Y.

Introduction: Glucose-dependent insulinotropic peptide (GIP) induces the cytokine interleukin (IL)-6 in adipocytes. IL-6 enhances insulin secretion from β-cells via L- and α-cell-derived GLP-1.Therefore we hypothesized that GIP regulates Glucagon-like peptide (GLP)-1 as well as glucose control via IL-6.Methods/Design: Basic research study on isolated human and mouse pancreatic islets and FACS-sorted human α-and β-cells that were treat...

ea0073oc4.1 | Oral Communications 4: Reproductive and Developmental Endocrinology | ECE2021

Effect of IL-1 receptor antagonism on hyperandrogenemia in women with polycystic ovary syndrome

Popovic Milica , Schiffer Lina , Taylor Angela E. , Arlt Wiebke , Vogt Deborah , De Geyter Christian , Sartorius Gideon , Donath Marc Y. , Christ-Crain Mirjam

BackgroundPolycystic Ovary Syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age. The main components are hyperandrogenemia and oligo-/amenorrhea. The pathophysiology of PCOS is not fully understood which is why no causal treatment options are available. A multitude of observational studies demonstrated elevated C-reactive protein (CRP) levels in patients with PCOS compared with weight-matched controls. CRP is a sensitive ...

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...